Low-Protein Diet with Low-Protein Foods Versus a LPD Without LP Foods in Patients with Chronic Kidney Disease (CKD)

Inclusion Criteria:

• CKD patient stage 3a-5 (<60 ml/min/1.73 m² estimated by CKD-EPI formula) and not ondialysis,

• With a good nutritional status (i.e., absence of malnutrition according to albumin,pre-albumine, BMI and no clinical and paraclinical criteria of malnutrition),

• Above 1g protein/ kg bw (ideal body weight),

• LPD-naïve patient,

• Motivated to LPD introduction (ensure during screening phase patient willingness tomodify diet habits with counselling accurate follow-up),

• Available to attend the visits planned by the protocol and able to complete the datacollection documents (diet record and self-administered questionnaires),

• Subject affiliated to a health insurance system or is a beneficiary (art. L.1121-11,Code of Public Health, France),

• Having given their informed written consent regarding its participation to theprotocol.

Exclusion Criteria:

• Patient for whom dialysis or transplantation is planned/expected within the next 12months

• Known allergic reactions to the ingredients present in FLAVIS products (milk, eggs,soy, nut),

• Uncontrolled Diabetes (HbA1C >8.5%),

• Active cancer (including a 5 years remission period),

• Psychiatric disorders or inability to follow the protocol,

• Evidence of any active infectious or uncontrolled inflammatory diseases,

• Inability to provide blood samples (poor venous capital),

• Inability to perform correct 24-hours urine collection,

• Any change of the chronic medication within 1 month before screening,

• Presence of any significant medical finding or significant history such asuncontrolled systemic diseases that may impact the safety, the interpretation of theresults and/or the participation of the subject in the study according to theopinion of the investigator,

• Patient with an active implanted medical device

• Simultaneous participation in another clinical trial or subject still within theexclusion period of a previous clinical trial.

• Vulnerable subjects (art. L. 1121-5 à 8 et L. 1122-1-2, Code of Public Health,France) are also excluded from the clinical trial.